Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: C00-D49- Neoplasms
Conditions
Interventions
Intervention1: Not applicable: Not applicable
Control Intervention1: Not applicable: Not applicable
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. Oncology patients admitted with RT-PCR confirmed COVID-19 illness 2. Age 1 to 80 years 3. Patients willing to consent for additional blood and nasopharyngeal swabs.
Exclusion criteria
Exclusion criteria: 1. ICU patients unable to give nasopharyngeal swab or blood sample for study proposes 2. Patients with other inter-current bacterial viral respiratory infections. 3. Patients in palliative therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the duration of persistence of replication-competent/infectious virus in oncology patients.Timepoint: At the baseline and at the time repeat nasopharyngeal swab if required as per standard reassessment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To establish correlation between RT-PCR (Ct value) and persistence of replication competent SARS-CoV-2Timepoint: At the baseline and at the time repeat nasopharyngeal swab if required as per standard reassessment;2. To identify cancer specific and chemotherapy regimen related risk factors for persistence of replication-competent virusTimepoint: At the baseline and at the time repeat nasopharyngeal swab if required as per standard reassessment;To evaluate whether specific cancer diagnoses or regimens of chemotherapy influence the occurrence of mutation in immune dominant regions in SARS-CoV-2 isolates from oncology patientsTimepoint: At the baseline and at the time repeat nasopharyngeal swab if required as per standard reassessment and during the chemotherapy as per the standards;To identify biomarkers (blood parameters like lymphocyte count neutrophil to lymphocyte ratio, inflammatory markers, viral serology) to predict clearance of replication-competent virus in oncology patients on chemotherapyTimepoint: At the baseline and at the time repeat nasopharyngeal swab if required as per standard reassessment;To identify presence of replication-competent virus in oncology patients who demonstrate a positive RT-PCR after two consecutive negative results(Re-infection)Timepoint: At the baseline and at the time repeat nasopharyngeal swab if required as per standard reassessment | — |
Countries
India
Contacts
Public ContactDr Chetan Dhamne
Tata Memorial Hospital
Outcome results
None listed